Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Wang SS, Yan Y (Susie), Ho K. US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives. Antib Ther. 2021;4:262–72.
2. Sánchez-félix M, Burke M, Chen HH, Patterson C, Mittal S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration : Open innovation challenge. Adv Drug Deliv Rev. 2020;167:66–77.
3. Garidel P, Kuhn AB, Schäfer LV, Karow-Zwick AR, Blech M. High-concentration protein formulations: How high is high? Eur J Pharm Biopharm. 2017;119:353–60. https://doi.org/10.1016/j.ejpb.2017.06.029.
4. Therapeutic Biological Establishment Evaluation Request (TB-EER) Form-Tocilizumab [Internet]. 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125472Orig1s000OtherR.pdf.
5. Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (Epinephrine) Injection for Potential Manufacturing Defect [Internet]. 2022. Available from: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/adamis-pharmaceuticals-corporation-issues-nationwide-voluntary-recall-symjepir-epinephrine-injection.